Brisbane-based medtech startup Proseek Bio has successfully closed an oversubscribed seed funding round, securing US$1 million. This capital will accelerate the development of its innovative OC-Triage blood test for ovarian cancer. The technology aims to address a critical issue where up to 80% of exploratory surgeries for suspected cases are performed on benign cysts.
Addressing a Critical Diagnostic Challenge
Currently, the only definitive method to determine if an ovarian cyst is cancerous is through invasive open surgery. This diagnostic uncertainty affects the one in five women who develop cysts, leading to a high rate of unnecessary procedures. These surgeries cause significant patient anxiety and place a considerable burden on healthcare systems.
The OC-Triage Innovation
Proseek Bio's OC-Triage test is a blood-based diagnostic tool designed to offer a more precise pre-surgical assessment. Its primary function is to help clinicians better differentiate between benign and malignant growths before any invasive action is taken. This will improve referral pathways, reduce delayed or unnecessary surgeries, and enhance clinical decision-making.
Founder Dr. Michelle Hill stated that previous biomarkers have lacked the necessary precision for widespread clinical use. She expressed confidence that Proseek Bio's technology can achieve the accuracy required for adoption into standard medical practice. This advancement is key to transforming the diagnostic landscape for one of the most serious cancers affecting women.
Strategic Investment for Clinical Progress
The A$1.5 million raised will be instrumental in advancing the OC-Triage test to its next crucial stage of development. The funds are earmarked for preparing the test for deployment in clinical laboratories and conducting the necessary validation studies. This process is essential for proving the test's efficacy and reliability in real-world clinical settings.
The funding round attracted a consortium of investors who recognize the significant opportunity in women's health. Key backers include Edale Capital, Scale Investors, AngelLoop, and AusHealth, demonstrating strong market confidence in Proseek Bio's mission. This investment signals a broader shift in capital towards addressing unmet clinical needs in this sector.
A Vision for Deployable Diagnostics
Proseek Bio's long-term vision extends beyond a single test, focusing on building deployable diagnostic platforms. The company aims to create solutions that integrate seamlessly into existing clinical workflows to maximize their impact. While ovarian cancer is the immediate priority, the underlying technology holds potential for other diagnostic applications in the future.
Beyond private investment, the startup has also garnered non-dilutive support from respected institutions. Backing from CSIRO, Advance Queensland, and the Brisbane Economic Development Agency provides a robust foundation for its work. This combination of public and private support underscores the project's scientific and commercial potential.
This successful seed round represents a significant milestone for Proseek Bio and a promising development in ovarian cancer diagnostics. With substantial financial backing and a clear strategic path, the company is poised to make a meaningful impact on patient care. The advancement of OC-Triage could soon provide a much-needed, less invasive tool for clinicians and women worldwide.